TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has provided an announcement.
Shanghai Henlius Biotech, Inc. announced that its investigational new drug application for HLX37, a recombinant humanised bispecific antibody targeting PD-L1 and VEGF, has been approved by the National Medical Products Administration for phase 1 clinical trials. HLX37 aims to treat advanced or metastatic solid tumors by simultaneously blocking PD-1/PD-L1 binding and inhibiting angiogenesis, showing promising pre-clinical results in tumor growth inhibition and safety. This development positions the company to potentially enhance its market presence in the bispecific antibody sector, although the successful commercialization of HLX37 is not guaranteed.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, specializing in the development of innovative biopharmaceuticals. The company focuses on creating recombinant antibodies, particularly targeting cancer treatment through advanced therapeutic pathways.
Average Trading Volume: 1,475,245
Technical Sentiment Signal: Buy
Current Market Cap: HK$37.53B
For a thorough assessment of 2696 stock, go to TipRanks’ Stock Analysis page.